SCHEMBL10147418

SCHEMBL10147418

CCOC(=O)C(=O)NCC(=O)c1ccc(C)cc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 6/20 0.47
HTT P42858 2/20 0.46
GAA P10253 2/20 0.46
PTPN1 P18031 1/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
TAS1R2 Q8TE23 1/20 0.42
HSD11B1 P28845 1/20 0.42
DHODH Q02127 1/20 0.41
MAPT P10636 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 2/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31301454 0.82 EGLN1 (0.54) EGLN1MEN1KMT2ASMN1; SMN2HTT
SCHEMBL10147411 0.81 SMN1; SMN2 (0.50) MEN1KMT2ASMN1; SMN2HTTGAA
SCHEMBL19814405 0.78 MAPT (0.50) EGLN1MEN1KMT2AGAAPTPN1
SCHEMBL11766232 0.77 SMN1; SMN2 (0.53) MEN1KMT2ASMN1; SMN2HTTGAA
SCHEMBL28455190 0.77 SMN1; SMN2 (0.51) MEN1KMT2ASMN1; SMN2HTTGAA
SCHEMBL29668381 0.76 MEN1 (0.60) MEN1KMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL1107151 0.76 MEN1 (0.60) MEN1KMT2ASMN1; SMN2RAB9ANPC1
SCHEMBL25207766 0.76 GAA (0.56) EGLN1MEN1KMT2ASMN1; SMN2HTT
SCHEMBL25279500 0.75 ALDH1A1 (0.48) EGLN1SMN1; SMN2GAAPTPN1TAS1R3
SCHEMBL22062254 0.74 KMT2A (0.49) MEN1KMT2ASMN1; SMN2HTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993556-B2 Resorcinol derivatives as HSP90 inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-03-31 US disclosed
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046266-A1 RESORCINOL DERIVATIVES AS HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90AB2P EGLN1 2598/4885MEN1 3746/4885KMT2A 3186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.